Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of Emvododstat (PTC299) in Relapsed/Refractory AML
NCT03761069Phase 1Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Oct 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emvododstat in acute myeloid leukemia (AML), sponsored by PTC Therapeutics, Inc. Primary endpoint: Number of Participants Who Discontinued Study Drug Due to Adverse Event. Started Oct 2018; status: terminated.
02
Drugs
emvododstat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03761069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761069.